Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Incidental gallbladder cancer (found after cholecystectomy), drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether T1b tumours need re-resection: two 2024 to 2026 analyses disagree on disease-specific benefit.
How many UK patients with an incidental cancer reach a hepatobiliary centre is not published.
Whether every gallbladder needs histological examination, or a selective policy based on age and the surgeon's inspection would be safe.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 3 changes by month →When this page itself was last checked or edited.
OS 51.
Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after.